Co-Diagnostics, Inc. Common Stock
CODXStock
$2.48−68.91%52W
Market Cap$13.14M
P/E—
Div yield—
Beta2.87
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-68.17%
Price vs S&P 500 (4W)-35.75%
VGM Score46.90
Market Capitalization$13.14M
Earnings Surprise History
Q1 26-4.06est. -3.83
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
2.29
2.29
2.29
2.29
Industry Peers — Surgical & Medical Instruments(141)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CODXCo-Diagnostics, Inc. Common Stock | B | D | C | $2.48 |
| SYKStryker Corporation | C | C | D | $331.20 |
| MMM3M Company | C | F | B | $161.77 |
| BSXBoston Scientific Corp. | C | B | F | $44.62 |
| MDLNMedline Inc. Class A common stock | C | D | D | $41.11 |
| BDXBecton, Dickinson and Co. | B | C | B | $159.93 |
| DXCMDexCom, Inc. | C | B | C | $77.98 |
| RMDResMed Inc. | C | B | D | $202.76 |
| WSTWest Pharmaceutical Services, Inc. | D | C | A | $362.44 |
| SOLVSolventum Corporation | C | D | B | $81.70 |
| PENPenumbra, Inc. | F | C | B | $319.60 |
About
Co-Diagnostics Inc is a molecular diagnostics company. The company develops, manufactures, licenses, and commercializes reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including molecular tools for detection of infectious diseases. CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and others. The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.